Abstract 829
Background
Different regimens of neoadjuvant radio-chemotherapy are concurrently used prior to surgery for resectable, locally advanced esophageal cancer. Comparative data are scarce and to some extent conflicting, regarding toxicity and long-term outcomes when treating different subtypes. This study aimed to assess clinical tolerances and long-term survival of three commonly used combinations of neoadjuvant therapies.
Methods
Patients operated from January 2004 to December 2014 who underwent neoadjuvant radio-chemotherapy with Paclitaxel/Carboplatin, or 5FU/Cisplatin, or FOLFOX for adenocarcinoma or squamous cell carcinoma were included. Seven European centers colligated data of 1188 patients. Cases with missing data (n = 147) or death <30 days postoperative (n = 51) were excluded. The primary outcome was the overall survival; secondary outcomes were the completeness and toxicity of neoadjuvant treatment, the disease free survival and the recurrence timing and pattern.
Results
Of the 990 eligible patients, Paclitaxel/Carboplatin was used in 598 patients (60%), 5FU/Cisplatin in 331 (33%) and Folfox in 61 (7%). The groups received a median radiation dose of 41.4 Gy, 45 Gy and 45 Gy (p = 0.65). Adenocarcinoma was the most frequent subtype (69%). No differences were detected in median overall survival (41 months, 34 months and 46 months, p = 0.251). Comparing the overall survival of the three regimens for adenocarcinoma vs squamous cell carcinoma, no difference was observed as well. There were no differences in chemotherapy-related morbidity (13%, 11% and 9%, p = 0.57), chemotherapy completeness (85%, 88% and 90%, p = 0.542) and radiotherapy completeness (98%, 99% and 96%, p = 0.9) between the three groups. Recurrence rates were similar (42%, 46% and 34%, p = 0.169), but median disease-free survival was improved in the 5FU/Cisplatin group (10 months, 18 months and 13 months, p < 0.001).
Conclusions
The overall survival did not differ between different neoadjuvant treatments. Moreover, no advantage of one regimen for specific cancer subtypes was observed. At most, a modest clinical advantage of 5-FU/Cisplatin was observed for disease-free survival.
Clinical trial identification
Research Registry number: 2157.
Legal entity responsible for the study
NeoTEC study group, Lausanne University Hospital, Lausanne, Switzerland.
Funding
Has not received any funding.
Editorial Acknowledgement
Disclosure
A.D. Wagner: Research funding: Roche; Consultant or advisory: Lilly, Celgene, Merck, Bristol-Myers Squibb, Pfizer, Servier Shire. M. van Berge Henegouwen: Medtronic, Olympus research grant (other studies). All other authors have declared no conflicts of interest.
Resources from the same session
1159 - Molecular characterization and search for founding effects in Canarian families with Hereditary Breast and Ovarian Cancer Syndrome
Presenter: Elisenda Llabres Valenti
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3725 - Effect of the polymorphism rs2066844 of the NOD2 gene on colon cancer incidence in a high cardiovascular risk population. Modulation by gender
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
3708 - Effect of the polymorphisms rs1476413, rs1801131, rs4846052 and rs6541003 of the MTHFR gene on prostate cancer in a high cardiovascular risk population
Presenter: Judith Begona Ramirez Sabio
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5057 - Association of a genetic variant in cyclin-dependent kinase Inhibitor 2A gene with the increased risk of breast cancer
Presenter: Soodabeh Shahid Sales
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5970 - Investigating the role of HAT protein TIP60 in regulating functional dynamics of nuclear receptor PXR
Presenter: KARISHMA BAKSHI
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1360 - The role of downregulated SIRT3 expression in patients with hepatocellular carcinoma
Presenter: Hanhee Jo
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1634 - Prediction and Intervention of Colorectal Cancer Risk with Artificial Intelligent System
Presenter: Yang Ge
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
4921 - Measuring the Efficiency of Cancer Care in Europe
Presenter: Rikard Althin
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
1235 - Circulating cell-free DNA isolated from plasma of mesenteric veins predicts prognosis in stage II colorectal cancer patients
Presenter: Chih-Yung Yang
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract
5169 - _lonality of uterine carcinosarcoma as a factor of clinical prognosis.
Presenter: Natalia Levitskaya
Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology
Resources:
Abstract